Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience.

Department of Neurological Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Journal of Neuro-Oncology (Impact Factor: 2.79). 06/2007; 83(1):61-70. DOI: 10.1007/s11060-006-9303-1
Source: PubMed

ABSTRACT Malignant gliomas are very difficult neoplasms for clinicians to treat. The reason for this is multifaceted. Many treatments that are effective for systemic cancer are unable to cross the blood-brain barrier and/or have unacceptable systemic toxicities. Consequently, in recent years an effort has been placed on trying to develop innovative local treatments that bypass the blood-brain barrier and allow for direct treatment in the central nervous system (CNS)-interstitial treatment. In this paper, we present our extensive experience in using interstitial chemotherapy as a strategy to treat malignant brain tumors at a single institution (The Johns Hopkins Hospital). We provide a comprehensive summary of our preclinical work on interstitial chemotherapy at the Hunterian Neurosurgery Laboratory, reviewing data on rat, rabbit, and monkey studies. Additionally, we present our clinical experience with randomized placebo-controlled studies for the treatment of malignant gliomas. We compare survival statistics for those patients who received placebo versus Gliadel as initial therapy (11.6 months vs. 13.9 months, respectively) and at the time of tumor recurrence (23 weeks vs. and 31 weeks, respectively). We also discuss the positive impact of local therapy in avoiding the toxicities associated with systemic treatments. Furthermore, we provide an overview of newer chemotherapeutic agents and other strategies used in interstitial treatment. Finally, we offer insight into some of the lessons we have learned from our unique perspective.

  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to evaluate the association between DNA methylation and multidrug resistance (MDR) in glioma and identify novel effectors responsible for MDR in human gliomas. An MDR glioma cell line, SGH‑44/ADM, was developed using adriamycin (ADM) impulse treatment. Cryopreservation, recovery and withdrawal were performed to evaluate the stability of SGH‑44/ADM cells. The adherence rate and cellular morphology were observed by microscopy, and the cell growth curve and doubling time were determined. DNA methylation was analyzed using a methylated DNA immunoprecipitation microarray chip (MeDIP‑Chip). The cell cycle, Rh123 ingestion and exudation, and SGH‑44/ADM apoptosis were analyzed by flow cytometry. SGH‑44/ADM cells showed little difference as compared with parental cells, except that SGH‑44/ADM cells were bigger in size with a wizened nucleus. Compared to SGH‑44 cells, a larger proportion of SGH‑44/ADM cells remained in G1 and S phase, as measured by flow cytometry. The MDR of SGH‑44/ADM was associated with the upregulation of multi‑drug resistance 1, prostaglandin‑endoperoxide synthase 2 (COX‑2); protein kinase C α (PKCα); however, the expression of these genes was not associated with DNA methylation. In the MeDIP‑Chip analysis, 74 functions were markedly enhanced, and seven significant pathways were observed. Genes including SNAP47, ARRB2, PARD6B, TGFB1, VPS4B and CBLB were identified by gene ontology analysis. The predominant molecular mechanism of MDR in SGH‑44/ADM cells was identified as exocytosis and efflux. The expression of COX‑2, PKCα and P‑glycoprotein (Pgp) was not found to be associated with DNA methylation. Genes including SNAP47, VAMP4 and VAMP3 may serve as the downstream effectors of Pgp, COX‑2 or PKCα; however, further experiments are required to verify these observations.
    Molecular Medicine Reports 10/2014; 11(1). DOI:10.3892/mmr.2014.2690 · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nanotechnology plays an increasingly important role not only in our everyday life (with all its benefits and dangers) but also in medicine. Nanoparticles are to date the most intriguing option to deliver high concentrations of agents specifically and directly to cancer cells; therefore, a wide variety of these nanomaterials has been developed and explored. These span the range from simple nanoagents to sophisticated smart devices for drug delivery or imaging. Nanomaterials usually provide a large surface area, allowing for decoration with a large amount of moieties on the surface for either additional functionalities or targeting. Besides using particles solely for imaging purposes, they can also carry as a payload a therapeutic agent. If both are combined within the same particle, a theranostic agent is created. The sophistication of highly developed nanotechnology targeting approaches provides a promising means for many clinical implementations and can provide improved applications for otherwise suboptimal formulations. In this review we will explore nanotechnology both for imaging and therapy to provide a general overview of the field and its impact on cancer imaging and therapy.
    Critical reviews in oncogenesis 01/2014; 19(3-4):143-176. DOI:10.1615/CritRevOncog.2014011601